Related Experiment Video
Updated: Jul 21, 2025
02:21
Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
697
Improvement in Endothelial Function in Men Taking Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction
Alex Konstantinovsky1, Nina Kuchersky1, Khalaf Kridin2
1The Department of Urology, Tzafon Medical Center, Azrieli Faculty of Medicine, Bar Ilan University, Ramat-Gan, Israel.
The American Journal of Medicine
|July 28, 2023
Summary
Phosphodiesterase-5 inhibitors (PDE5-Is) improved erectile dysfunction and endothelial function in men. This suggests a potential mechanism for reducing cardiovascular events in this population.
Area of Science:
- Cardiovascular Medicine
- Urology
- Pharmacology
Background:
- Erectile dysfunction (ED) and endothelial dysfunction are early indicators of atherosclerosis.
- Previous studies suggest PDE5-Is reduce cardiovascular events in men with ED and prior myocardial infarction.
Purpose of the Study:
- To investigate the cardiovascular protective mechanisms of PDE5-Is in men with ED.
- To explore the correlation between improved endothelial function and ED treatment outcomes.
Main Methods:
- A pilot study involving 5 men with ED but no cardiovascular disease.
- Tadalafil (5 mg daily) was administered for 3 months.
- Measurements included endothelial function (brachial artery flow-mediated dilation), ED grade, hs-CRP, and BMI.
Main Results:
- A significant positive correlation was found between improvements in endothelial function and ED grade (P=.010, r=0.959).
- No significant changes were observed in hs-CRP or body mass index.
Conclusions:
- PDE5-Is significantly improve both endothelial function and erectile dysfunction in men.
- Enhanced endothelial function may be the key mechanism by which PDE5-Is reduce cardiovascular risk.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
189
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
189
01:28Nitric Oxide Signaling Pathway
5.1K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.1K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
201
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
201
01:23Antihypertensive Drugs: Vasodilators
568
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
568
01:17Male Sexual Response: Erection & Ejaculation
2.9K
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
2.9K